Checkpoint Inhibitors: Global Markets

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Immuno-Oncology Market and Checkpoint Market Statistics

Immuno-Oncology
-Co-Stimulatory Immune Checkpoint Targets
-Inhibitory Immune Checkpoint Targets
-Immunometabolic Modulatory Targets
Unmet Medical Needs
-New Biomarkers to Stratify Patients
-Relapse/Refractory Patients
-Treatment Efficacy and Tolerability
Innovative Strategies
-Emerging New Checkpoint Inhibitors
-New Combinations
Novel Targeted Approaches
-Humanized Monoclonal Antibodies
-Bispecific Agents
-CAR-T Cells
Current Market Landscape
-Marketed Checkpoint Inhibitors
-Developmental Checkpoint Inhibitors

Chapter 4 PD-1/PD-L1 Agents

Introduction
Marketed
-Pembrolizumab (Keytruda), Merck & Co.
-Companion Diagnostic
-Clinical Trial Program
-Pembrolizumab Forecasts
Nivolumab (Opdivo), BMS
-Companion Diagnostic
-Clinical Trial Program
-Nivolumab Forecasts
Atezolizumab (Tecentriq), Genentech
-Companion Diagnostic
-Clinical Trial Program
-Atezolizumab Forecasts
Avelumab (Bavencio), Merck KGaA/Pfizer
-Companion Diagnostic
-Clinical Trial Program
-Avelumab Forecasts
Durvalumab (Imfinzi), AstraZeneca
-Companion Diagnostic
-Clinical Trial Program
-Durvalumab Forecasts
-Cemiplimab (Libtayo), Regeneron/Sanofi
Clinical Programs Phase 3
-Spartalizumab, Novartis
-Tislelizumab, BeiGene
Clinical Programs Phase 2
-INCMGA0012, Incyte/MacroGenics
-LY3300054, Eli Lilly
Clinical Programs Phase 1
-BI 754091, Boehringer Ingelheim
-CA-170, Curis/Aurigene
-CS1001, CStone Pharmaceuticals
-FS118, Merck KGaA/F-Star
Preclinical Programs
-aCD27xaPD-L1, Celldex
-MEDI1109, AstraZeneca
-XmAb20717 and XmAb23104, Xencor
Market Forecasts

Chapter 5 CTLA-4

Introduction
Marketed Drugs
-Yervoy (ipilimumab), BMS
Clinical Programs Phase 3
-Tremelimumab, Astra Zeneca
Clinical Programs Phase 1/2
-Anti-CTLA-4/PD-1 Expressing MUC1-CAR-T, Shanghai Cell Therapy
Clinical Programs Phase 1
-AGEN-1884, Agenus
-BCD-145, Biocad
-CS1002, CStone Pharmaceuticals
-REGN4659, Regeneron Pharmaceuticals
Market Forecasts

Chapter 6 IDO-1

Introduction
IDO-1 Developmental Therapies
Clinical Programs Phase 3
-Epacadostat, Incyte
Clinical Programs Phase 1
-BMS 986205, Bristol-Myers Squibb
-EOS200271, iTeos Therapeutics
-Indoximod (NLG-001) and Navoximod (NLG 919, GDC-0919, R6078), NewLink Genetics
-KHK2455, Kyowa Kirin
-LY3381916, Eli Lilly
Preclinical Programs
Market Forecasts

Chapter 7 LAG-3

Introduction
LAG-3 Developmental Therapies
Clinical Programs Phase 2/3
-Relatlimab (BMS-986016), BMS
Clinical Programs Phase 2
-LAG525 (IMP701), Novartis/Immuntep (Prima BioMed)
-Eftilagimod Alpha (IMP321), Immuntep (Prima BioMed)
-BI 754111, Boehringer Ingelheim
-FS118, Merck KGgaA/ F-star
-Sym022, Shire/Symphogen A/S
-TSR-033, Tesaro/Anaptys Bio
-XmAb22841, Xencor
Preclinical Programs
-INCAGN02385, Incyte/Agenus
Market Forecasts

Chapter 8 TIM-1,3

Introduction
TIM-1,3 Developmental Therapies
Clinical Programs Phase 2
-Bavituximab, Merck Sharp & Dohme/Oncologie International
Clinical Programs Phase 1/2
-CDX-014, Celldex Therapeutics/Seattle Genetics
-MGB453 +/- Spartalizumab, Novartis
Clinical Programs Phase 1
-LY3321367 +/- LY3300054, Eli Lilly
-TSR-022 +/- TSR-042, Tesaro/AnaptysBio
Preclinical Programs
-CA-327 (AUPM-327), Curis/Aurigene
-ENUM005, Enumeral Biomedical
-JNJ-64158120, Johnson & Johnson
-LY3321367, Eli Lilly
-STI-600, Sorrento Therapeutics
-Sym016, Symphogen A/S
Market Forecasts

Chapter 9 CD47/SIRPa

Introduction
CD47-SIRPa Developmental Therapies
Clinical Phase 1/2
-5F9, Forty Seven Inc
Clinical Programs Phase 1
-ALX148, ALX Oncology
-CC-90002, Celgene/InhibRx
-SRF231, Surface Oncology
-TTI-621, Trillium
-TTI-622, Trillium
Preclinical Programs
-OSE-172, Boeringher Ingelheim/ OSE Immunotherapeutics
-INCAGN2390, Incyte/Agenus
Market Forecasts

Chapter 10 Company Profiles

ALX ONCOLOGY
AGENUS INC.
ANAPTYS BIO
BEIGENE
BIOCAD
CSTONE PHARMACEUTICALS
CRESCENDO BIOLOGICS LTD.
F-STAR BIOTECHNOLOGY
FORTY SEVEN, INC.
IMMUTEP, LTD.
INHIBRX
MACROGENICS, INC.
OSE IMMUNOTHERAPEUTIC
REGENERON PHARMACEUTICALS, INC.
SEATTLE GENETICS, INC.
SORRENTO THERAPEUTICS, INC.
SHANGHAI CELL THERAPY
SYMPHOGEN A/S
SURFACE ONCOLOGY
TESARO, INC.
TRILLIUM THERAPEUTICS
XENCOR

Chapter 11 Appendix A: List of Abbreviations

Chapter 12 Appendix B: Glossary of Terms

Chapter 13 Appendix C: Sources"

List of Tables

Summary Table : Global Market for Checkpoint Inhibitors, by Drug Class, Through 2023
Table 1 : Adverse Events Associated with Immune-Checkpoint Blockade
Table 2 : Global Market for Marketed Checkpoint Inhibitors, by Drug Target, Through 2023
Table 3 : Global Market for Developmental Checkpoint Inhibitors, by Drug Target, Through 2023
Table 4 : Comparison of PD-L1-PD-L2 ligands
Table 5 : Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
Table 6 : PD-1/PD-L1 Agents in Development
Table 7 : Pembrolizumab Approved Indications
Table 8 : Global Market for Pembrolizumab, by Region, Through 2023
Table 9 : Global Market for Pembrolizumab, by Indication, Through 2023
Table 10 : Nivolumab Approved Indications
Table 11 : Global Market for Nivolumab, by Region, Through 2023
Table 12 : Global Market for Nivolumab, by Indication, Through 2023
Table 13 : Atezolizumab Approved Indications
Table 14 : Global Market for Atezolizumab, by Region, Through 2023
Table 15 : Global Market for Atezolizumab, by Indication, Through 2023
Table 16 : Avelumab Approved Indications
Table 17 : Global Market for Avelumab, by Region, Through 2023
Table 18 : Global Market for Avelumab, by Indication, Through 2023
Table 19 : Durvalumab Approved Indications
Table 20 : Global Market for Durvalumab, by Region, Through 2023
Table 21 : Global Market for Duvalumab, by Indication, Through 2023
Table 22 : Regeneron’s NSCLC Development Program
Table 23 : Global Market for Cemiplimab, by Region, Through 2023
Table 24 : Global Market for Cemiplimab, by Indication, Through 2023
Table 25 : Clinical Trials Evaluating Tislelizumab
Table 26 : Clinical Trials Evaluating INCMGA00012
Table 27 : Global Market for anti-PD-1/PD-L1 Therapies, by Product, Through 2023
Table 28 : CTLA-4 Agents in Development
Table 29 : Global Market for Anti-CTLA-4 Therapies, by Product, Through 2023
Table 30 : Summary of Anti-IDO-1 Developmental Programs
Table 31 : Clinical Trials Evaluating Epacadostat
Table 32 : Clinical Trials Evaluating Navoximod (GDC-0919)
Table 33 : Global Market for anti-IDO-1 Therapies, by Product, Through 2023
Table 34 : Anti- LAG-3 Therapies in Development
Table 35 : Clinical Trials Evaluating Relatlimab
Table 36 : Clinical Trials Evaluating LAG525
Table 37 : Clinical Trials Evaluating IMP321
Table 38 : Clinical Trials Evaluating BI 754111
Table 39 : Clinical Trials Evaluating FS118
Table 40 : Clinical Trials Evaluating Sym022
Table 41 : Clinical Trials Evaluating TSR-033
Table 42 : Global Market for anti-LAG-3 Therapies, by Product, Through 2023
Table 43 : TIM-1,3 Agents in Development
Table 44 : Global Market for Anti-TIM-1,3 Therapies, by Product, Through 2023
Table 45 : T-Cell and Macrophages Characteristics
Table 46 : Clinical Trials Evaluating CD47-SIRPα Targeted Therapies
Table 47 : Clinical Trials Evaluating 5F9
Table 48 : Clinical Trials Evaluating ALX148
Table 49 : Clinical Trials Evaluating C-9002
Table 50 : Clinical Trials Evaluating C-9002
Table 51 : Clinical Trials Evaluating TTI-621
Table 52 : Clinical Trials Evaluating TTI-622
Table 53 : Global Market for anti-CD47-SIRPα Therapies, by Product, Through 2023
Table 54 : Abbreviations Used in Checkpoint Inhibitors
Table 55 : Glossary of Terms
Table 56 : Checkpoint Inhibitors Sources
Table 57 : Chapter 2 Sources
Table 58 : Chapter 3 Sources
Table 59 : Chapter 4 Sources
Table 60 : Chapter 5 Sources
Table 61 : Chapter 6 Sources
Table 62 : Chapter 7 Sources
Table 63 : Chapter 8 Sources"

List of Figures

Summary Figure : Global Market for Checkpoint Inhibitors, by Drug Class, 2017-2023
Figure 1 : Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 2 : Global Market for Marketed Checkpoint Inhibitors, by Drug Target, 2017-2023
Figure 3 : Global Market for Developmental Checkpoint Inhibitors, by Drug Target, 2017-2023
Figure 4 : Pembrolizumab Comprehensive Clinical Trial Programs, by Status
Figure 5 : Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 6 : Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 7 : Global Market for Pembrolizumab, by Region, 2017-2023
Figure 8 : Nivolumab Comprehensive Clinical Trial Programs, by Status
Figure 9 : Nivolumab Comprehensive Clinical Trial Programs, by Therapy
Figure 10 : Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 11 : Global Market for Nivolumab, by Region, 2017-2023
Figure 12 : Atezolizumab Comprehensive Clinical Trial Programs, by Status
Figure 13 : Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 14 : Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 15 : Global Market for Atezolizumab, by Region, 2017-2023
Figure 16 : Avelumab Comprehensive Clinical Trial Programs, by Status
Figure 17 : Avelumab Comprehensive Clinical Trial Programs, by Therapy
Figure 18 : Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 19 : Global Market for Avelumab, by Region, 2017-2023
Figure 20 : Durvalumab Comprehensive Clinical Trial Programs, by Status
Figure 21 : Durvalumab Comprehensive Clinical Trial Programs, by Therapy
Figure 22 : Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 23 : Global Market for Durvalumab, by Region, 2017-2023
Figure 24 : Global Market for Cemiplimab, by Region, 2017-2023
Figure 25 : Global Market for anti-PD-1/PD-L1, by Product, 2017-2023
Figure 26 : Signaling Molecules Involved in CD28 and CTLA-4 Function
Figure 27 : Fab Fragment of ipilimumab (blue) Binding CTLA-4 (green)
Figure 28 : Global Market for Anti-CTLA-4 Therapies, by Product, 2017-2023
Figure 29 : Schematic of Mechanism of Action of IDO-1 Inhibition on Tryptophan (Trp) Catabolism in Cancer
Figure 30 : Structure of Epacadostat
Figure 31 : Structure of BMS-986205
Figure 32 : Structure of A) Inoximod and B) navoximod
Figure 33 : Global Market for anti-IDO-1 Therapies, by Product, 2017-2023
Figure 34 : Global Market for Anti-LAG3 Therapies, by Product, 2017-2023
Figure 35 : Schematic of Mechanism of Action of TIM-3 in T-Cell Activation and Synergistic Effect on PD-1 Inhibition
Figure 36 : Global Market for Anti-TIM-1,3 Therapies, by Product, 2017-2023
Figure 37 : Mechanism of Action of Anticd47/SIRPα Therapies
Figure 38 : Structure of ALX148
Figure 39 : Structure of TTI-621
Figure 40 : Structure of TTI-622
Figure 41 : Global Market for anti-CD47-SIRPα, by Product, 2017-2023

当レポートのプレスリリースは発行されておりません。